ArticlePloS one2025
Insufficient impact of the aldose reductase inhibitor cemtirestat on the skeletal system in type 2 diabetic rat model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Effects of the Most Common Polyphenols Found inNutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cemtirestat, a multi-target drug combining aldose reductase inhibition with antioxidant properties, is considered a promising therapeutic agent for chronic diabetic complications. Current evidence suggests that long-standing diabetes adversely affects skeletal health, leading to diabetic bone disease. As the impact of cemtirestat on the skeletal system in an animal model of type 2 diabetes mellitus (T2DM) is still unknown, our study first investigated its effect on impaired bone health in Zucker diabetic fatty (ZDF) rats. Adult rats were divided into four groups: L (untreated lean ZDF rats), D (untreated obese ZDF rats), DT2.5 (obese ZDF rats treated with 2.5 mg/kg/day cemtirestat), and DT7.5 (obese ZDF rats treated with 7.5 mg/kg/day cemtirestat), with cemtirestat treatment lasting 2 months. Group D had increased levels of plasma glucose, insulin, triglycerides, glycated hemoglobin, total cholesterol, alkaline phosphatase, alanine aminotransferase, C-terminal telopeptide of type 1 collagen, greater body weight, femoral weight, structure model index, reduced cortical bone volume fraction, cortical bone thickness, trabecular bone volume fraction, and trabecular thickness compared to group L. Cemtirestat supplementation only elevated plasma phosphate levels in group DT2.5, trabecular bone volume fraction and trabecular thickness in group DT7.5, but the treatment had no effect on other parameters demonstrated in ZDF rats by macroscopic analysis, micro-CT cortical bone analysis, and mechanical testing. These findings indicate that the efficacy of cemtirestat in restoring deteriorated bone health caused by T2DM is not substantiated due to its insufficient effect on the skeletal system in the ZDF rat model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.